Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Closes CLIA Lab Acquisition

NEW YORK (GenomeWeb News) – Trovagene today said it has completed its acquisition of the CLIA laboratory of MultiGen Diagnostics.

Trovagene announced the deal with the privately held molecular diagnostic subsidiary of Bio-ID Diagnostics in early January. The lab is certified by the State of California in compliance with CLIA and is accredited by the College of American Pathologists.

As part of the deal, Trovagene is issuing 750,000 shares of its common stock with an additional earn-out of up to $3.7 million in cash and common stock, subject to the lab achieving specific sales and earnings targets.

MultiGen continues to operate as a molecular diagnostics company focused on DNA sequencing-based identification services.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.